Assessing Surgical Extent Before Biologic Therapy for CRSwNP

IF 4.9 2区医学 Q1 OTORHINOLARYNGOLOGY

International Forum of Allergy & Rhinology Pub Date : 2026-09-04 Epub Date: 2026-07-20 DOI:10.1002/alr.70220

Alison J. Yu, Kristina A. LaPointe, Kaitlyn Ann Roberts, Michelle Yu, James N. Palmer, Alan D. Workman, Jose L. Mattos, Rodney J. Schlosser, Zachary M. Soler

引用次数: 0

Abstract

Key Points

Nearly two-thirds of patients had no surgery or incomplete sinus surgery before biologics.
Among all sinuses, the frontal sinus was the least frequently addressed before biologics.

查看原文本刊更多论文

CRSwNP生物治疗前手术范围评估。

要点：近三分之二的患者在使用生物制剂前没有手术或不完全鼻窦手术。在所有的鼻窦中，额窦是在生物制剂之前最少被处理的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Forum of Allergy & Rhinology OTORHINOLARYNGOLOGY-

CiteScore

11.70

自引率

10.90%

发文量

185

审稿时长

6-12 weeks

期刊介绍： International Forum of Allergy & Rhinologyis a peer-reviewed scientific journal, and the Official Journal of the American Rhinologic Society and the American Academy of Otolaryngic Allergy. International Forum of Allergy Rhinology provides a forum for clinical researchers, basic scientists, clinicians, and others to publish original research and explore controversies in the medical and surgical treatment of patients with otolaryngic allergy, rhinologic, and skull base conditions. The application of current research to the management of otolaryngic allergy, rhinologic, and skull base diseases and the need for further investigation will be highlighted.